Enobosarm (GTx) is published in The Lancet Oncology

The Lancet Oncology, has published online ahead of its April print edition the results from the randomized, double-blind, placebo-controlled Phase II clinical trial of Enobosarm from GTx to assess its effects on Muscle Wasting and physical function in patients with cancer.

Enobosarm (GTx-024) is a selective androgen receptor modulator (SARM), a new class of non-steroidal, tissue-specific anabolic agents that has the potential to increase muscle mass and improve physical function without the unwanted side effects on the prostate, skin or hair that are commonly associated with testosterone or non-selective, synthetic anabolic steroids. The lead author was Dr. Adrian S. Dobs, Professor of Medicine at the Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine in Baltimore, Maryland.

see-The Lancet Oncology, Early Online Publication, 14 March 2013- doi:10.1016/S1470-2045(13)70055-XCite or Link Using DOI "Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial"- Prof Adrian S Dobs MD et al.